4930548H24Rik Inhibitors

The chemical class known as Ccdc121 Inhibitors encompasses a range of compounds that indirectly affect the function of coiled-coil domain containing 121 (Ccdc121) by targeting various cellular pathways and processes. These compounds have been identified based on their known action on cellular mechanisms that could intersect with the functional landscape of Ccdc121. For instance, microtubule-targeting agents such as colchicine, paclitaxel, vinblastine, and nocodazole are known to disrupt the dynamics of the cytoskeleton, to which coiled-coil domain proteins, including Ccdc121, could be spatially or functionally related.

Furthermore, compounds like forskolin, Y-27632, and rapamycin target signaling pathways that might regulate the expression or interaction of coiled-coil domain proteins. Forskolin, by elevating cAMP levels, and rapamycin, by inhibiting mTOR, can modulate protein synthesis and degradation pathways. Inhibitors such as MG-132 and cycloheximide directly affect the stability and synthesis of proteins, respectively, which could impact the levels of Ccdc121. Chlorpromazine and Brefeldin A affect membrane-associated processes, and geldanamycin targets protein chaperones like Hsp90, which are essential for the correct folding and function of a broad range of proteins, including those with coiled-coil domains.